Drug Profile
ACT 101
Alternative Names: ACT-101Latest Information Update: 28 Nov 2020
Price :
$50
*
At a glance
- Originator Alpha Cancer Technologies
- Class Recombinant proteins
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Inflammatory bowel diseases; Multiple sclerosis; Myasthenia gravis; Thyroiditis
Most Recent Events
- 28 Nov 2020 No recent reports of development identified for phase-I development in Inflammatory-bowel-diseases in USA (PO)
- 28 Nov 2020 No recent reports of development identified for phase-I development in Multiple-sclerosis in USA (PO)
- 28 Nov 2020 No recent reports of development identified for phase-I development in Myasthenia-gravis in USA (SC)